Regeneron Pharmaceuticals, Inc. officer Joseph LaRosa filed a Form 144 notice on November 2, 2026, proposing the sale of 4,466 shares of common stock on NASDAQ, with an aggregate market value of $4,311,875.12.

Key Highlights

  • Seller: Joseph LaRosa, an officer of Regeneron Pharmaceuticals, Inc.
  • Shares proposed for sale: 4,466 shares of common stock, with an aggregate market value of $4,311,875.12.
  • Approximate date of sale: November 2, 2026, on NASDAQ.
  • Source of shares: Stock option exercise completed on January 3, 2024, acquiring 9,507 shares from the company, with stock as the form of payment.
  • Broker: UBS Financial Services Inc., 1000 Harbor Blvd, 3rd Floor, Weehawken, NJ 07086.
  • Shares outstanding: 101,630,713 shares of common stock as reported in the filing.
  • Prior three-month sales: Nothing to report, according to the filing.

LaRosa's Proposed Rule 144 Sale of Regeneron Common Stock

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Joseph LaRosa, identified as an officer of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), proposed to sell 4,466 shares of Regeneron common stock. The filing lists an aggregate market value of $4,311,875.12 for the proposed sale, with the approximate date of sale given as November 2, 2026. The broker named in the filing is UBS Financial Services Inc., located in Weehawken, New Jersey.

The filing discloses that the shares proposed for sale were acquired through a stock option exercise on January 3, 2024, with the company identified as the person from whom the shares were acquired. The nature of payment recorded in the filing is stock, and the total amount of securities acquired in that transaction was 9,507 shares. The filing reports 101,630,713 shares of common stock outstanding.

The Form 144 was signed by Mijo Suric, for UBS Financial Services Inc., as attorney-in-fact for Joseph LaRosa. The filing states that LaRosa had no prior sales of Regeneron securities to report during the three months preceding the notice date. The filing also notes that the signatory represents that he does not know any material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed.

What Was Disclosed

Regeneron Pharmaceuticals officer Joseph LaRosa filed a Form 144 notice of proposed sale of 4,466 shares of common stock, valued at $4,311,875.12 in aggregate, acquired via a January 3, 2024 stock option exercise. No sales were reported in the prior three months.